FOURIER Update -Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab - ESC 2017

 

This interview with Robert Giugliano from Brigham and Women's Hospital, Boston, US discusses the Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab (A FOURIER Update) at ESC 2017.